ACTG382 PHARMACOKINETICS, SAFETY, TOLERABILITY&ANTIVIRAL ACTIVITY OF

ACTG382 药代动力学、安全性、耐受性

• 批准号: 6264880
• 负责人: MARGARET A KELLER
• 金额: $ 0.1万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264880
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; child (0-11); clinical research; clinical trial phase I; combination chemotherapy; dosage; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; pharmacokinetics; protease inhibitor; reverse transcriptase inhibitors

This is a clinical study of DMP 266, an investigational drug being studied for the treatment of HIV infection in children. This study will try to find out if DMP 266 is safe and effective for children and determine the proper dosage in children. This drug will be taken in combination with the FDA approved drug Nelfinavir(NFV). The study will also determine the appropriate dose of NFV in children when given in combination with DMP 266.These medicines will be taken in addition to the usual anti-HIV medicine the patient is already taking like AZT, d4T, ddI or 3TC. The dose of the medicines may change depending on the results of these pharmacokinetic studies.

这是对DMP 266的临床研究，DMP 266是一种正在研究的治疗儿童艾滋病毒感染的研究药物。这项研究将试图找出DMP 266对儿童是否安全有效，并确定儿童的适当剂量。该药物将与FDA批准的药物奈非那韦(NFV)联合服用。这项研究还将确定儿童服用NFV的合适剂量，当与DMP 266联合服用时，这些药物将是患者已经服用的常用抗艾滋病毒药物如AZT、D4T、DDI或3TC的补充。药物的剂量可能会根据这些药代动力学研究的结果而变化。